Condition: Metastatic Triple-Negative Breast Carcinoma · Sponsor: Fundacio Clinic Barcelona
This is a prospective, multicenter, phase I/II, open-label, two-stage design of PD1+ TILs infusion in metastatic or advanced TNBC. TILS001 includes 3 parts. Previous to each phase inclusion, a specific ICF must be signed by the patient. Participants potentially eligible to participate in the clinical trial will be offered to sign a ICF three times prior to TILs treatment: 1) to allow for collection of archival FFPE tissue samples for determination PD1 by mRNA (Part #1), 2) prior to a fresh metastatic biopsy for selection, isolation and partial expansion of PD1+ TILs (Part #2) and 3) prior to allow for remaining study procedures and TILs therapy (Part #3, Main Consent).
This description comes directly from the study's public registry record.
Tomás Pascual · + 34 933 436 302 · tomas.pascual@gruposolti.org
Laura Angelats · LANGELATS@clinic.cat
Always discuss trial participation with your own doctor first.
| Hospital Universitari Vall d'Hebrón | Barcelona, Spain | Recruiting |
| Hospital Clinic de Barcelona | Barcelona, Spain | Recruiting |
| Hospital 12 de Octubre | Madrid, Spain | Recruiting |
| Clínica universidad de Navarra | Pamplona, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05451784